Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07185425

Impact of the NeuroCuple Device on Pain Management After Cesarean Delivery

This will be a single-center, sham-controlled, 3 arms, randomized (1:1:1) prospective study in females undergoing cesarean delivery to investigate the impact of NeuroCuple™ non-pharmacological analgesic device for management of postoperative pain. The investigators hypothesize that women treated with the Neurocuple device will experience less pain and consequently require less opioid pain medication after cesarean delivery compared to women who receive standard post-surgical medication.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Inova Fairfax Medical Campus

Falls Church, Virginia, 22042, United States

Location status: Recruiting

Location contact

Antonio Saad, MD

CONTACT

[email protected]

703-776-6040

Antonio Saad, MD

PRINCIPAL_INVESTIGATOR

Elle Murrin, MD

SUB_INVESTIGATOR

Maggie Wong, MD

SUB_INVESTIGATOR

Michelle Cassidy, PhD, RN

CONTACT

[email protected]

(703) 776-4600

About this study

This is a single-center, sham-controlled, 3-arms, randomized, prospective study in 180 women undergoing cesarean delivery, with an expected subject enrollment duration of one year. Subjects will be screened and consented preoperatively before the scheduled case. Enrolled subjects will be randomized by research personnel using a computer generated randomization scheme in a 1:1:1 group allocation and assigned to the active device, sham device, or standard of care arms.

Upon arrival to the PACU, subjects in the standard-of-care arm will receive standard postoperative pain orders at the discretion of the primary OB/GYN. For subjects in the active and sham device arms, device will be placed as soon as feasible in the PACU and before transfer to the post-partum floor by trained research staff. Both patients and the clinical team will be blinded to the group assignment for the active and sham devices.

Pain scores will be collected from the study participants per nursing protocols while inpatient, and daily after discharge until postoperative day 4, using the Pain Numeric Rating Scale. For breakthrough pain, patients may use oral or IV opioids in the inpatient setting and oral opioids in the outpatient setting.

Upon discharge, patients are typically prescribed an opioid medication. However, this will also be left to the discretion of the primary OB/GYN. In this study, the investigators will examine total milligram morphine equivalent (MME) opioid intake at postoperative day 4 or before discharge as the primary endpoint, reduction (percentage change) in numeric pain scale as the secondary endpoint, and change in quality of recovery as the exploratory endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female 18 years or older able to provide informed consent in English or Spanish
  • Scheduled for a planned or unplanned non-emergent cesarean delivery under neuraxial anesthesia
  • Intact skin surfaces around the operative skin incision area at the site of patch application
  • Pfannestiel skin incision

Exclusion criteria

  • Active drug abuse
  • Chronic opioid user
  • Severe chronic pain
  • Psoriasis vulgaris or other skin conditions precluding safe device application
  • Subject is concurrently participating in another research study with an investigational drug or medical device that in the Investigator's opinion could impact subject safety or study results
  • Subject with reasons to maintain an epidural beyond operative room
  • Subject with complex surgery or subject who may need more than a cesarean surgery with possible tubal sterilization procedure
  • Subject is deemed not suitable for the study at the discretion of the principal Investigator

Treatment and study plan

NeuroCuple

Device

Device around the abdomen over c-section bandages in the PACU

SHAM

Device

Device around the abdomen over c-section bandages in the PACU

Primary outcomes

  1. Total Milligram Morphine Equivalents (MME)

    Time frame: Day of surgery to postop day 4

    Total opioid intake in MME on postoperative days 4 or before discharge.

Secondary outcomes

  1. Pain reduction

    Time frame: Day of surgery to postop day 4

    Reduction (percentage decrease) in pain score (0-10 numeric rating scale) from day of surgery through postoperative day 4.

  2. Quality of Recovery

    Time frame: Day of surgery to postop day 4

    Quality of recovery assessment evaluated on postoperative days 1-4 (Swedish Web Version of Quality of Recovery (SwQoR))

  3. Opioid-related adverse events

    Time frame: Day of surgery to postop day 4

    Overall incidence of opioid-related adverse effects including maternal PONV, sedation, constipation in POD 0-4

Study contacts

Contact information is provided by the study sponsor or research team.

Antonio Saad, MD

CONTACT

[email protected]

7037766040

Michelle Cassidy, phD

CONTACT

[email protected]

7037764600

Sponsors and collaborators

Lead sponsor

Inova Health Care Services

Other

Collaborators

  • nCap Medical

Registry information

Official study title

Management of Postoperative Pain After Cesarean Delivery Using Non-pharmacological Analgesic Device, NeuroCuple™

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 22, 2025
Registry last updated
Oct 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.